Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Prospective Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

NCT05806580 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05806580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05806580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Prospective Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
May 1, 2023
Completion date
December 31, 2027
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory b-cell lymphoma